Court Opinion

ID: 150891
Source: CourtListenerOpinion
Date Created: 2010-07-17 00:01:26+00
Date Added: 2024-06-11T12:31:43.837331
License: Public Domain

Case: 09-30446        Document: 00511176837              Page: 1       Date Filed: 07/16/2010

            IN THE UNITED STATES COURT OF APPEALS
                     FOR THE FIFTH CIRCUIT  United States Court of Appeals
                                                     Fifth Circuit

                                                  FILED
                                                                                       July 16, 2010

                                             No. 09-30446                              Lyle W. Cayce
                                                                                            Clerk

IN RE: VIOXX PRODUCTS LIABILITY LITIGATION

------------------------------------------------------------------------------------------------

GLENN L. DIER, ET AL.,

                                                          Plaintiffs - Appellants
v.

MERCK AND COMPANY, INC., A Foreign Corporation

                                                          Defendant - Appellee

                      Appeal from the United States District Court
                          for the Eastern District of Louisiana
                                USDC No. 2:05-MD-1657

Before GARWOOD, STEWART, and CLEMENT, Circuit Judges.
PER CURIAM:*
        In this mass tort multidistrict litigation (MDL) proceeding, thousands of
plaintiffs alleged personal injuries resulting from the use of Vioxx, a drug
manufactured by defendant Merck and Company, Inc. (Merck). Many of the

        *
         Pursuant to 5TH CIR . R. 47.5, the court has determined that this opinion should not
be published and is not precedent except under the limited circumstances set forth in 5TH CIR .
R. 47.5.4.
   Case: 09-30446    Document: 00511176837      Page: 2    Date Filed: 07/16/2010

                                    No. 09-30446

litigants have arrived at an opt-in Master Settlement Agreement (MSA) to
resolve claims for those plaintiffs who meet certain criteria. Glenn L. Dier and
his fellow plaintiffs-appellants (the Dier plaintiffs) have not opted into the MSA.
The district court issued a series of pre-trial orders, including pre-trial order 28
(PTO 28), which required that non-settling plaintiffs each produce a report from
a doctor linking the alleged injury to use of Vioxx. The district court issued a
show cause order for the Dier plaintiffs’ failure to comply with PTO 28 and later
dismissed the Dier plaintiffs’ cases on that basis. We AFFIRM.
            I. FACTUAL AND PROCEDURAL BACKGROUND
      In September 2004, Merck withdrew Vioxx from the market when data
revealed an increased risk of cardiovascular thrombotic events associated with
the drug. See In re Vioxx Prods. Liab. Litig., 401 F. Supp. 2d 565, 571 (E.D. La.
2005). Litigation soon followed and thousands of claims were filed around the
country. Id.
      1. Multidistrict Litigation
       In February 2005, the Judicial Panel on Multidistrict Litigation ordered
that the Vioxx litigation be “centralized, designated as an MDL, and assigned to”
Judge Eldon Fallon. Id. Judge Fallon then directed the parties to address
whether a class of personal injury plaintiffs could be certified under Rule 23. In
November 2006, he denied certification of a nationwide class because the
plaintiffs’ claims raised choice-of-law hurdles and numerous individualized
questions of fact. In re Vioxx Prods. Liab. Litig., 239 F.R.D. 450, 458–59, 461
(E.D. La. 2006).
      2. The Master Settlement Agreement
      Settlement negotiations resulted in the MSA, which the parties presented
to the district court on November 9, 2007. The MSA established threshold
criteria for plaintiffs’ eligibility to opt in. Section 1.2.8 of the MSA imposed the
requirement that any plaintiffs’ counsel enrolling clients in the MSA must affirm

                                         2
   Case: 09-30446      Document: 00511176837         Page: 3    Date Filed: 07/16/2010

                                      No. 09-30446

that she had recommended to 100% of her clients that they accept the terms of
the MSA and must attempt to withdraw from representing clients who refused
to accept the MSA terms. The MSA also designated Judge Fallon as its chief
administrator.
       3. The Pre-trial Orders
       On November 9, 2007 the district court entered several pre-trial orders
with respect to the claims of those plaintiffs who could not or chose not to
participate in the MSA. PTO 281 required non-settling plaintiffs to notify their
healthcare providers that they must preserve evidence pertaining to the
plaintiffs’ use of Vioxx. Plaintiffs were also required to produce pharmacy
records and medical authorizations, answers to interrogatories, and a Rule
26(a)(2) report from a medical expert attesting that the plaintiff sustained an
injury caused by Vioxx and that the injury occurred within a specified time
period. Failure to comply could result in dismissal of the plaintiffs’ claims with
prejudice.2
       Pre-trial order 30 (PTO 30) imposed a stay of discovery so that plaintiffs
could consider the MSA, with exceptions for discovery activities required by PTO
28 and previously scheduled de bene esse depositions. Pre-trial order 31 (PTO 31)
enforced the terms of Section 1.2.8 of the MSA by requiring all counsel of record
for plaintiffs to register all claims in which they had an interest and sign a
“Registration Affidavit,” in which they had to attest to whether they agreed to
the terms of the MSA and would recommend that their clients enroll in the MSA.

       1
        PTO 28 is characterized as a Lone Pine order, named for Lore v. Lone Pine Corp., No.
L-33606-85, 1986 WL 637507 (N.J. Super. Ct. Law Div. Nov. 18, 1986). “Lone Pine orders are
designed to handle the complex issues and potential burdens on defendants and the court in
mass tort litigation.” Acuna v. Brown & Root Inc., 200 F.3d 335, 340 (5th Cir. 2000).
       2
        Pre-trial Order 29 (PTO 29) is virtually identical to PTO 28, differing primarily
because it applies to plaintiffs whose claims were transferred to the MDL after November 9,
2007 and therefore sets different deadlines.

                                             3
   Case: 09-30446      Document: 00511176837         Page: 4    Date Filed: 07/16/2010

                                      No. 09-30446

       4. Dier Plaintiffs’ Dismissal
       The Dier plaintiffs brought their Vioxx suits against Merck in state and
federal courts in New York. Each case was then transferred to the MDL. The
Dier plaintiffs have not opted into the MSA.
       Shortly after the MSA was announced and the pre-trial orders were
entered, a group of plaintiffs (the Oldfather plaintiffs) filed a motion in the
district court requesting modification or suspension of PTO 28 on the basis that
its requirements were premature and unfairly burdensome. The district court
rejected the Oldfather plaintiffs’ arguments, but nonetheless extended the
deadlines for PTO 28 “to ensure that all Plaintiffs have a fair opportunity to
comply with this provision of PTO 28.” In re Vioxx Prods. Liab. Litig., 557 F.
Supp. 2d 741, 745 (E.D. La. 2008).
       One month after the Oldfather ruling, in June 2008, another group of
plaintiffs (the Agard plaintiffs)3 filed a motion making substantially the same
arguments as the Oldfather plaintiffs in opposition to PTO 28. They requested
another extension and sought to eliminate the expert report requirement of PTO
28. The Agard plaintiffs also argued that Judge Fallon’s roles as MSA chief
administrator and as coordinating judge of the MDL proceeding created an
incurable conflict of interest, requiring Judge Fallon to resign as MSA
administrator. They further asserted that the MSA should be vacated or
declared void because it had not been subject to the requirements of Rule 23. In
December 2008, the district court denied the Agard motion in its entirety.
       In October 2008, the district court entered an order (the Conference Order)
instructing eligible but non-settling plaintiffs to appear at one of three
conferences to be held in different locations nationally. The stated purpose of the
order was “to ensure that plaintiffs who are eligible for the Vioxx settlement

       3
         The Agard plaintiffs were also represented by the Law Office of Ronald R. Benjamin,
counsel for the Dier plaintiffs. The Agard plaintiffs included some of the Dier plaintiffs.

                                             4
   Case: 09-30446    Document: 00511176837     Page: 5   Date Filed: 07/16/2010

                                  No. 09-30446

program but who have not enrolled in the program . . . have all necessary
information available to them so that they can make informed choices.” The
order directed counsel and plaintiffs themselves to appear in person at one of the
conferences, although it expressly allowed plaintiffs to avoid this requirement
for reasons of “physical or economic hardship.” Many of the Dier plaintiffs
claimed hardship and were excused from attendance. The Dier plaintiffs also
moved the district court to vacate the order, contending that the only conceivable
purpose of the conferences was for the court to engage in “advocacy for the
settlement in an environment that is necessarily going to be viewed as coercive
by the individual plaintiffs.” The district court denied the motion.
      In November 2008, Merck moved for an Order to Show Cause as to
sixty-one plaintiffs (including the Dier plaintiffs) for “failure to provide a
case-specific expert report as required by . . . PTO 28.” In December 2008, the
district court issued an Order to Show Cause. The Dier plaintiffs filed responses,
arguing that they were in substantial compliance with PTO 28 and that New
York law only required general causation proof. In April 2009, the district court
dismissed the Dier plaintiffs’ complaints with prejudice for failure to comply
with PTO 28.
                               II. DISCUSSION
A. Standing to Challenge the MSA
      The Dier plaintiffs first challenge the validity of the MSA. Standing,
however, is a prerequisite to this court’s exercise of jurisdiction. Doe v.
Tangipahoa Parish Sch. Bd., 494 F.3d 494, 496 n.1 (5th Cir. 2007) (en banc).
This court has recognized that, in the context of class settlements, non-settling
parties generally have no standing to challenge the settlement. Transam.
Refining Corp. v. Dravo Corp., 952 F.2d 898, 900 (5th Cir. 1992); see also Agretti
v. ANR Freight Sys., 982 F.2d 242, 246 (7th Cir. 1992) (“‘[N]on-settling
defendants in a multiple defendant litigation context have no standing to object

                                        5
   Case: 09-30446    Document: 00511176837      Page: 6    Date Filed: 07/16/2010

                                  No. 09-30446

to the fairness or adequacy of the settlement by other defendants.’”) (quoting 2
H ERBERT B. N EWBERG, N EWBERG ON C LASS A CTIONS § 11.54 (2d ed. 1985)). The
rationale behind this general rule is that settlement will not affect any
substantive legal rights of non-settling parties. Transam. Refining Corp., 952
F.2d at 900.
      An exception to the general rule may apply if the settlement agreement
strips non-settling parties of rights to contribution or indemnity, see id., or in
some other manner results in “plain legal prejudice” to a non-settling party.
Agretti, 982 F.2d at 246–47; see also Bass v. Phoenix Seadrill/78, Ltd., 749 F.2d
1154, 1160 n.10 (5th Cir. 1985) (stating that the court may consider “an attempt
by a non-party to the settlement to void portions of the agreement that purport
to affect the rights of non-settlors”). But “[m]ere allegations of injury in fact or
tactical disadvantage as a result of a settlement simply do not rise to the level
of plain legal prejudice.” Agretti, 982 F.2d at 247.
      Because the MSA was structured as an “opt-in” private settlement rather
than an “opt-out” agreement, the Dier plaintiffs cannot show that they have
suffered the type of legal prejudice that would afford them standing to challenge
the MSA. The Dier plaintiffs therefore lack standing to challenge the MSA.
B. Judge Fallon’s Decision to Not Recuse
      The Dier plaintiffs contend that Judge Fallon cannot serve as both
presiding judge in the Vioxx MDL and chief administrator of the MSA without
presenting the appearance of partiality. They assert that Judge Fallon’s dual
roles “clearly permit[ ] an inference” that he encouraged participation in the
MSA. Therefore, they argue, Judge Fallon must either recuse himself from the
case or resign as chief administrator of the MSA.
      Addressing the Dier plaintiffs’ contentions in its order of December 10,
2008, the district court declined to recuse on the basis that:

                                         6
   Case: 09-30446     Document: 00511176837      Page: 7    Date Filed: 07/16/2010

                                   No. 09-30446

      The facts of the instant case do not warrant recusal. As Chief
      Administrator of the [MSA], the Court serves in an administrative
      capacity that has no substantive effect on its management of the
      MDL proceedings. See In re Vioxx Prods. Liab. Litig., MDL No.
      1657, 2008 WL 4091672, at *2 (E.D. La. Aug. 27, 2008) (explaining
      that the Court “has consistently exercised its inherent authority
      over the MDL proceedings in coordination with its express authority
      under the terms of the Settlement Agreement to ensure that the
      settlement proceedings move forward in a uniform and efficient
      manner”). The Court played no role in drafting the private
      settlement agreement reached by the parties; the Court has taken
      no position as to what types of claims should or should not have
      been included in the settlement; and, finally, the Court has
      consistently stated that it neither encourages nor discourages
      participation in the settlement.
      “A motion to disqualify is committed to the sound discretion of the judge
and her decision will only be reversed if there has been an abuse of that
discretion.” In re Hipp, Inc., 5 F.3d 109, 116 (5th Cir. 1993). The federal recusal
statute provides that “[a]ny justice, judge, or magistrate judge of the United
States shall disqualify himself in any proceeding in which his impartiality might
reasonably be questioned.” 28 U.S.C. § 455. “The very purpose of § 455(a) is to
promote confidence in the judiciary by avoiding even the appearance of
impropriety whenever possible.” Liljeberg v. Health Servs. Acquisition Corp., 486
U.S. 847, 865 (1988) (citing S. R EP. N O. 93-419, at 5 (1974) and H.R. R EP. N O. 93-
1453, at 5 (1974)). “Thus, it is critically important in a case of this kind to
identify the facts that might reasonably cause an objective observer to question
[the judge’s] impartiality.” Id. In applying § 455, the court employs an objective
test, finding recusal warranted“if the reasonable man, were he to know all the
circumstances, would harbor doubts about the judge’s impartiality.” IQ Prods.
Co. v. Pennzoil Prods. Co., 305 F.3d 368, 378 (5th Cir. 2002) (quotation omitted).
      1. Encouraging Participation in Settlement
      The Dier plaintiffs submit that the district court’s statement that it “has
consistently stated that it neither encourages nor discourages participation in

                                          7
   Case: 09-30446    Document: 00511176837      Page: 8   Date Filed: 07/16/2010

                                  No. 09-30446

the settlement” takes “too myopic a view” of the court’s role as both chief
administrator of the MSA and as presiding judge in the MDL litigation. They
point to the Conference Order, which required all non-settling plaintiffs to
appear at conferences “to ensure that plaintiffs who are eligible for the Vioxx
settlement program but who have not enrolled in the program have all necessary
information available to them so they can make informed choices,” and argue
that this order permits the inference that the district court encouraged
settlement. The Conference Order, however, did not inappropriately encourage
settlement. It “is not unusual to require the parties as well as counsel to appear
at settlement conferences.” Bilello v. Abbott Labs., 825 F. Supp. 475, 479
(E.D.N.Y. 1993). For example, Federal Rule of Appellate Procedure 33 authorizes
courts of appeals to “direct the attorneys—and, when appropriate, the
parties—to participate in one or more conferences to address any matter that
may aid in disposing of the proceedings, including . . . discussing settlement. A
judge or other person designated by the court may preside over the conference.”
F ED. R. A PP. P. 33. Nothing about the settlement conferences would give a
reasonable observer any doubt about Judge Fallon’s impartiality.
      2. Appearance of Partiality
      In support of their argument that the district court’s impartiality could
reasonably be questioned, the Dier plaintiffs assert that at least one plaintiff
lacked confidence in the district court’s impartiality as a result of its dual
responsibilities. But because the test for impartiality is an objective one, see IQ
Prods. Co., 305 F.3d at 378, an individual plaintiff’s subjective beliefs are
irrelevant to the analysis.
      For the reasons articulated by Judge Fallon, his decision not to recuse falls
well within the bounds of his discretionary authority.
C. Pre-Trial Order 28 Requiring Production of a Doctor’s Report

                                        8
   Case: 09-30446    Document: 00511176837      Page: 9   Date Filed: 07/16/2010

                                  No. 09-30446

      The Dier plaintiffs’ final argument is that it was an abuse of discretion for
the district court to issue the case-specific expert disclosure requirement in PTO
28. They contend that Merck was aware of the nature of their alleged injuries
and the injuries’ purported link to Vioxx. They further assert that even if
issuance of PTO 28 was generally within the district court’s discretion, in
instances where state law requires no expert opinion as part of the evidence to
support the claim, imposing such a requirement is an abuse of discretion and
contravenes the Erie doctrine. See Erie R.R. Co. v. Tompkins, 304 U.S. 64, 78–80
(1938).
      1. The Court and Merck were Already Apprised of Plaintiffs’ Injuries
      A district court’s adoption of a Lone Pine order and decision to dismiss a
case for failing to comply with a Lone Pine order are reviewed for abuse of
discretion. Acuna, 200 F.3d at 340–41.
      Relying on Acuna, the district court stated that “it is not too much to ask
a plaintiff to provide some kind of evidence to support their claim that Vioxx
caused them personal injury.” In re Vioxx Prods. Liab. Litig., 557 F. Supp. 2d at
744. In Acuna, over 1,000 plaintiffs brought personal injury claims allegedly
arising from uranium mining activities. The district court issued pre-discovery
Lone Pine orders that required plaintiffs to provide expert affidavits specifying
the injuries suffered by each plaintiff, the substances causing the injury, the
dates and circumstances of exposure to the injurious materials, and the scientific
and medical bases for the expert’s opinions. Acuna, 200 F.3d at 338. The district
court ultimately dismissed plaintiffs’ claims for failure to comply with the Lone
Pine orders. Id. at 340. On appeal, plaintiffs challenged the Lone Pine orders as
imposing too high a burden at too early a stage in the litigation. Id. This court
stated that “[i]n the federal courts, such orders are issued under the wide
discretion afforded district judges over the management of discovery under F ED.
R. C IV. P. 16.” Id. The court then held that the Lone Pine orders

                                         9
  Case: 09-30446       Document: 00511176837          Page: 10     Date Filed: 07/16/2010

                                       No. 09-30446

       essentially required that information which plaintiffs should have
       had before filing their claims pursuant to F ED. R. C IV. P. 11(b)(3).
       Each plaintiff should have had at least some information regarding
       the nature of his injuries, the circumstances under which he could
       have been exposed to harmful substances, and the basis for
       believing that the named defendants were responsible for his
       injuries.
Id. (citing Beanal v. Freeport-McMoran, Inc., 197 F.3d 161, 165 (5th Cir. 1999)).
Thus, the Acuna court concluded that the district court did not commit an abuse
of discretion by dismissing plaintiffs’ claims for failure to comply with the Lone
Pine order. Id. at 341.
       The Dier plaintiffs contend that this case is distinguishable from Acuna
because here the plaintiffs have alleged precise injuries and both the court and
Merck are on notice of the nature of the injuries and the injuries’ relationship to
Merck’s conduct. These grounds are insufficient, however, to warrant bypassing
the clear holding in Acuna that it is within a court’s “discretion to take steps to
manage the complex and potentially very burdensome discovery that the cases
would require.” Id. at 340.
       2. Requirement of Proof of Physical Injury for Emotional Distress Claims
       The Dier plaintiffs also argue that PTO 28 was improper because expert
testimony is not required for claims of negligent infliction of emotional distress
under New York law.4 But the Dier plaintiffs all pleaded physical injuries, and
none attempted to withdraw those physical injury claims. Thus, PTO 28 would
apply regardless of whether the Dier plaintiffs might have had a viable negligent
infliction of emotional distress claim along with their physical injury claims.
                                   III. CONCLUSION
       For the foregoing reasons, we AFFIRM the judgment of the district court.

       4
         “[T]he substantive law of each plaintiff’s home jurisdiction must be applied to his or
her respective claims.” In re Vioxx Prods. Liab. Litig., 239 F.R.D. 450, 458 (E.D. La. 2006).

                                              10